Article
VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer.
Oncotarget - 8 Dec 2015
Schafroth Christian, Galván José A, Centeno Irene, Koelzer Viktor H, Dawson Heather E, Sokol Lena, Rieger Gregor, Berger Martin D, Hädrich Marion, Rosenberg Robert, Nitsche Ulrich, Schnüriger Beat, Langer Rupert, Inderbitzin Daniel, Lugli Alessandro, Zlobec Inti
Abstract excerpt
AIM: VE1 is a monoclonal antibody detecting mutant BRAFV(600E) protein by immunohistochemistry. Here we aim to determine the inter-observer agreement and concordance of VE1 with mutational status, investigate heterogeneity in colorectal cancers and metastases and determine the prognostic effect of VE1 in colorectal cancer patients. METHODS: Concordance of VE1 with mutational status and inter-observer agreement...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
- Biomarkers, Tumor
- Biopsy
- Colorectal Neoplasms
- DNA Mutational Analysis
- Female
- Germany